Leerink Swann

Analysts at Leerink Swann initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Outperform rating. The target price for ACADIA Pharmaceuticals is set to $48. ACADIA Pharmaceuticals shares have gained 92.90% over the past 52 weeks, while the S&P 500 index has surged 12.97% in...

Leerink Swann downgraded Cellular Dynamics International, Inc. (NASDAQ: ICEL) from Outperform to Market Perform. The price target for Cellular Dynamics has been raised from $11 to $16.50. Cellular Dynamics shares have gained 36.93% over the past 52 weeks, while the S&P 500 index has surged 13....

Analysts at Leerink Swann initiated coverage on Invitae Corporation (NYSE: NVTA) with a Market Perform rating. The target price for Invitae is set to $20. Invitae's shares rose 2.35% to close at $18.70 on Friday.

Analysts at Leerink Swann initiated coverage on HealthEquity, Inc. (NASDAQ: HQY) with a Outperform rating. The target price for HealthEquity is set to $28. HealthEquity's shares rose 1.13% to close at $21.50 on Friday.

Analysts at Leerink Swann upgraded The Medicines Company (NASDAQ: MDCO) from Market Perform to Outperform. The price target for Medicines Company has been raised from $24 to $31. Medicines Company shares have declined 36.78% over the past 52 weeks, while the S&P 500 index has gained 9.63% in...

Analysts at Leerink Swann upgraded Boston Scientific Corporation (NYSE: BSX) from Market Perform to Outperform. The price target for Boston Scientific has been raised from $15 to $18. Boston Scientific shares have surged 9.78% over the past 52 weeks, while the S&P 500 index has gained 10.22...

Analysts at Leerink Swann downgraded Kindred Biosciences (NASDAQ: KIN) from Outperform to Market Perform. The price target for Kindred Biosciences has been lowered from $11.25 to $6. Kindred Biosciences' shares fell 0.22% to close at $9.24 yesterday.

Analysts at Leerink Swann initiated coverage on WebMD Health (NASDAQ: WBMD) with a Outperform rating. The target price for WebMD Health is set to $60. WebMD Health shares have gained 9.81% over the past 52 weeks, while the S&P 500 index has surged 11.64% in the same period. WebMD Health's...

Analysts at Leerink Swann upgraded MedAssets (NASDAQ: MDAS) from Market Perform to Outperform. The target price for MedAssets is set to $26. MedAssets shares have fallen 6.51% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period. MedAssets' shares rose 0.28% to...

Analysts at Leerink Swann initiated coverage on shares of ITC Holdings (NYSE: ITC) with a Outperform rating. The target price for ITC Holdings is set to $34. ITC Holdings shares have surged 23.26% over the past 52 weeks, while the S&P 500 index has gained 14.74% in the same period. ITC Holdings...

Analysts at Leerink Swann upgraded Allergan (NYSE: AGN) from Market Perform to Outperform. The target price for Allergan is set to $184. Allergan shares have surged 64.59% over the past 52 weeks, while the S&P 500 index has gained 12.49% in the same period. Allergan's shares dropped 3.30% to...

In a report published Tuesday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating and $106.00 price target on Aegerion Pharmaceuticals (NASDAQ: AEGR). In the report, Leerink Swann noted, “This afternoon we spoke with AEGR management who continued to highlight its confidence...

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on WellPoint (NYSE: WLP) with an Outperform rating and $104.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E EPS from...

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on UnitedHealth Group (NYSE: UNH) with a Market Perform rating and $77.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E...

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on WellCare Health Plans (NYSE: WCG) with a Market Perform rating and $72.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to...